Lansdale, Pennsylvania (PRWEB) November 01, 2011
JDP Therapeutics Inc., a privately held, clinical stage specialty pharmaceutical company, today announced positive results for a Phase I clinical study for JDP-207, a novel treatment for acute allergic reactions being developed by JDP. JDP-207 was well tolerated in the clinic, and demonstrated faster drug absorption and better tolerability with a modified formulation. The study was a randomized, single-center, single-dose, two-way crossover pilot study to evaluate JDP-207 in healthy human volunteers. The parameters measured in the study included pharmacokinetics, drug absorption, safety, tolerability, and injection site irritation.
“These results demonstrate that JDP’s proprietary technology can safely provide therapeutic drug levels efficiently without having significant adverse events. This modified formulation shows its flexibility in controlling drug absorption rate. This pilot study paves the way for an upcoming pivotal clinical trial on JDP-207,” said Jie Du, Ph.D., President and CEO of JDP Therapeutics.
JDP-207 is a proprietary drug product, and first-in-class therapy being developed for the treatment of acute allergic reactions for patients’ self-administration. Acute allergic reaction is a serious condition, potentially life-threatening, and has been growing at an alarming rate in the last two decades due to increased human exposure to ever growing varieties of food and pharmaceuticals. Currently there are very limited selections of medication. JDP-207 will offer a new method and a superior treatment for patients suffering from acute allergic reactions.
About JDP Therapeutics Inc.
JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.
JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.
For further information, please email info(at)jdptherapeutics(dot)com
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP’s product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP’s ability to fund such efforts with or without partners, and other risks.